查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529802

新生儿毒理学市场规模、份额、趋势分析报告：按检体、按药物、按技术、按最终用途、按地区、细分市场预测，2024-2030 年

Neonatal Toxicology Market Size, Share & Trends Analysis Report By Specimen (Urine, Umbilical Cord), By Drug (Cannabinoids, Opioids), By Technology, By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

新生儿毒理学市场成长与趋势：

根据Grand View Research, Inc.最新报告，预计到2030年，全球新生儿毒性市场规模将达到5.1405亿美元，预计2024年至2030年复合年增长率为10.6%。

由于孕产妇吸毒导致的新生儿禁忌症（NAS）等新生儿疾病的盛行率不断增加，推动了对新生儿毒理学检测和治疗的需求。此外，质谱仪等先进诊断技术的发展正在改善新生儿有毒物质暴露的检测和管理，从而推动市场成长。

这一令人震惊的趋势凸显了对有效的新生儿毒性解决方案的迫切需求。在过去的几十年里，药物筛检工具取得了显着进步，现在可以提供比以往更准确和精确的结果。传统上，药物测试是使用酵素结合免疫吸附检测法（ELISA）进行的。这种方法有几个优点。它相对便宜，易于在一般实验室中执行，并且週转时间短。此外，由于 ELISA 多年的使用，一些市售抗体已被检验可用于多种人体组织。对于某些测试，例如检测尿液中的可卡因代谢物，ELISA 是一种可靠的方法。然而，其他药物和组织组合的假阳性和阴性发生率相对较高。

此外，马萨诸塞州最大的医疗保健系统麻省总医院布里格姆分校宣布将在 2024 年 4 月对婴儿出生时暴露于毒品的可疑虐待或忽视行为的报告方式进行重大改变。耶鲁纽黑文儿童医院和波士顿医疗中心等系统也采用了这一政策转变，这是针对怀孕期间吸毒采取更加富有同情心、基于证据的应对措施的更广泛努力的一部分，它显示了一种趋势。这些机构不会报告所有出生时接触药物的案例，而是只会报告他们有合理理由相信婴儿面临身体或心理伤害风险的病例。这种方法反映了一种日益增长的共识，即惩罚性措施会导致父母和儿童的健康状况恶化，并对有色人种家庭和社会经济地位较低的家庭产生不成比例的影响。这种不断变化的政策格局对新生儿毒理学检测产业具有重大影响。从惩罚性方法转向更具支持性和康復性的措施预计将推动新生儿毒理学检测的需求和利用的变化。

康乃狄克州、新墨西哥州、华盛顿州和科罗拉多等州法律的变化，以及麻州一项悬而未决的法案，旨在保护服用处方药治疗药物滥用障碍的母亲，测试标准可能会变得更加复杂。这可能会导致更有针对性的测试，更有效地利用资源，并且仅在绝对必要时进行测试。此外，随着市场转向支持性护理，提供全面、微创筛检解决方案的新技术具有巨大的成长潜力。这包括高解析度质谱和创新生物标记等技术的进步，使我们能够更详细地了解新生儿的暴露和健康状况，而无需进行重大侵入性手术。

新生儿毒理学市场报告亮点

  • 根据检体，胎粪在 2023 年的收益占有率最大。粪便检体透过检测怀孕后期的药物暴露，提供更长的检测窗口，在新生儿毒性方面具有重要优势。
  • 质谱法是新生儿毒性的黄金标准，为检测纳克级药物暴露提供无与伦比的灵敏度和特异性。其优点包括准确度高、检测极限低以及能够从初步筛检中确认阳性结果。
  • 从药物来看，大麻素细分市场占据主导地位，2023 年市场占有率最大。怀孕期间大麻素的使用呈上升趋势，有 2-5% 的孕妇自我报告使用大麻素，其中低收入都市区女性的比例高达 28%。这种增加是由于合法化、安全意识以及用于噁心。
  • 按最终用途划分，临床测试领域在 2023 年占据最大的销售份额。 Arup Laboratories 和 Quest Diagnostics 是市场上的主要参与者，提供全面的检测服务来检测产前药物暴露。
  • 由于存在大量主要市场参与者、新生儿药物暴露率高以及对产前药物滥用的不良影响的认识不断增强，北美在市场上占据主导地位。
  • 预计 2024 年至 2030 年预测期内，亚太地区将呈现最快的复合年增长率。扩大医疗基础设施和实施旨在减少怀孕期间药物滥用的公共卫生倡议预计将推动该地区的市场成长。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章新生儿毒理学市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 新生儿毒理学市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章 新生儿毒性市场：检体估计与趋势分析

  • 2023年及2030年按检体分類的市场占有率份额
  • 细分仪表板
  • 检体的全球新生儿毒性市场前景
  • 2018-2030年市场规模、预测及趋势分析

第五章新生儿毒理学市场：技术估算与趋势分析

  • 2023 年和 2030 年按技术市场占有率
  • 细分仪表板
  • 按技术展望分類的全球新生儿毒理学市场
  • 2018-2030年市场规模、预测及趋势分析

第六章新生儿毒性市场：依药物类型估计与趋势分析

  • 2023 年和 2030 年按药物类型分類的市场占有率份额
  • 细分仪表板
  • 按药物类型分類的全球新生儿毒性市场前景
  • 2018-2030年市场规模、预测及趋势分析

第七章新生儿毒理学市场：最终用户的估计和趋势分析

  • 2023 年和 2030 年最终用户的市场占有率
  • 细分仪表板
  • 按最终用户分類的全球新生儿毒性市场前景
  • 2018-2030年市场规模、预测及趋势分析

第八章新生儿毒理学市场：区域估计和趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模及预测趋势分析：
  • 北美洲
    • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
    • Quest Diagnostics Incorporated
    • USDTL
    • Quidel Corporation
    • Thermo Fisher Scientific, Inc.
    • Omega Laboratories, Inc.
    • Bio-Rad Laboratories, Inc.
    • Agilent Technologies, Inc.
    • Laboratory Corporation of America Holdings
    • Clinical Reference Laboratory, Inc.
    • Cordant Health Solutions
Product Code: GVR-4-68040-358-5

Neonatal Toxicology Market Growth & Trends:

The global neonatal toxicology market size is expected to reach USD 514.05 million by 2030, at a projected CAGR of 10.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of neonatal disorders, such as neonatal abstinence syndrome (NAS) due to maternal drug use, drives the demand for neonatal toxicology testing and treatments. In addition, the development of advanced diagnostic technologies, such as mass spectrometers, improves the detection and management of toxic exposures in neonates, thereby propelling market growth.

This alarming trend underscores the urgent need for effective neonatal toxicology solutions. Over the past several decades, there have been significant advancements in drug screening tools, which now provide more accurate and precise results than ever before. Traditionally, drug testing has been performed using enzyme-linked immunosorbent assays (ELISAs). This method has several advantages: it is relatively inexpensive, easy to perform in a general laboratory, and has a rapid turnaround time. Moreover, the long-standing use of ELISA has resulted in the availability of multiple commercial antibodies validated for use in various human tissues. For certain tests, such as detecting cocaine metabolites in urine, ELISA is a reliable method. However, for other drug and tissue combinations, there is a relatively high incidence of both false positives and negatives.

In addition, Mass General Brigham, Massachusetts' largest healthcare system, in April 2024 announced a significant shift in its approach to reporting suspected abuse or neglect in cases where a baby is born exposed to drugs. This policy change, now adopted by systems like Yale New Haven Children's Hospital and Boston Medical Center, signifies a broader trend toward more compassionate and evidence-based responses to substance use during pregnancy. Rather than reporting every instance of drug exposure at birth, these health systems will only report if there is reasonable cause to believe the infant is at risk of physical or emotional injury. This approach reflects a growing consensus that punitive measures lead to worse medical outcomes for both parent and child and disproportionately impact families of color and those with low socioeconomic status. This evolving policy landscape has profound implications for the neonatal toxicology testing industry. The shift away from punitive approaches towards more supportive and rehabilitative measures is expected to drive changes in the demand and utilization of neonatal toxicology tests.

With revised state laws in places like Connecticut, New Mexico, Washington, and Colorado and pending legislation in Massachusetts to protect mothers on prescribed medications for substance use disorder, the criteria for conducting toxicology tests may become more refined. This could lead to more targeted testing, ensuring that resources are used efficiently and that testing is conducted only when truly necessary. In addition, as the market shifts towards supportive care, there is significant potential for growth in emerging technologies that offer comprehensive and minimally invasive screening solutions. This includes advancements in technologies like high-resolution mass spectrometry and innovative biomarkers that can provide more detailed insights into neonatal exposure and health without extensive invasive procedures.

Neonatal Toxicology Market Report Highlights:

  • Based on the specimen, meconium accounted for the largest revenue share in 2023. Meconium specimens offer a key advantage in neonatal toxicology by detecting drug exposure over the last trimester of pregnancy, providing a longer detection window.
  • Based on technology, mass spectroscopy dominated the market in 2023.Mass spectrometry is the gold standard in neonatal toxicology, offering unparalleled sensitivity and specificity for detecting drug exposure at nanogram levels. Its advantages include high accuracy, low detection limits, and the ability to confirm positive results from initial screenings.
  • Based on the drug, the cannabinoids segment dominated the market in 2023 with the largest market share. Cannabinoid use during pregnancy is rising, with 2-5% of pregnant women self-reporting use and rates as high as 28% among low-income urban women. This increase is driven by legalization, perceived safety, and use for nausea.
  • Based on end use, the clinical laboratories segment dominated the market with the largest revenue share in 2023. Arup Laboratories and Quest Diagnostics are key players in the market, providing comprehensive testing services to detect prenatal drug exposure.
  • North America dominated the market due to the presence of a large number of major market players, the high prevalence of neonatal drug exposure, and the increasing awareness of the adverse effects of prenatal drug abuse.
  • The Asia Pacific region is expected to witness the fastest CAGR over the forecast period from 2024 to 2030. Due to the expansion of healthcare infrastructure and the implementation of public health initiatives aimed at reducing drug abuse during pregnancy, market growth is expected in this region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Specimen
    • 1.2.2. Technology
    • 1.2.3. Drug
    • 1.2.4. End User
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Specimen outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Drug outlook
    • 2.2.4. End User outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Neonatal Toxicology Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. High prevalence of substance abuse
      • 3.2.1.2. Stringent laws mandating alcohol and drug testing
      • 3.2.1.3. Increasing government initiatives to monitor substance abuse
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Neonatal toxicology is considered a violation of privacy rights in some countries
  • 3.3. Neonatal Toxicology Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Neonatal Toxicology Market: Specimen Estimates & Trend Analysis

  • 4.1. Specimen Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Neonatal Toxicology Market by Specimen Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Urine
      • 4.4.1.1. Urine market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Umbilical Cord
      • 4.4.2.1. Umbilical cord market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Meconium
      • 4.4.3.1. Meconium market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Neonatal Toxicology Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Neonatal Toxicology Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Mass spectroscopy
      • 5.4.1.1. Mass spectroscopy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Immunoassay
      • 5.4.2.1. Immunoassay market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Neonatal Toxicology Market: Drug type Estimates & Trend Analysis

  • 6.1. Drug type Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Neonatal Toxicology Market by Drug type Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Cannabinoids
      • 6.4.1.1. Cannabinoids Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Opioids
      • 6.4.2.1. Opioids Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Cocaine
      • 6.4.3.1. Cocaine Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Benzodiazepines
      • 6.4.4.1. Benzodiazepines market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Amphetamines
      • 6.4.5.1. Amphetamines Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Other illicit drugs
      • 6.4.6.1. Other illicit drugs Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Neonatal Toxicology Market: End User Estimates & Trend Analysis

  • 7.1. End User Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Neonatal Toxicology Market by End User Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Hospitals
      • 7.4.1.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Clinical Laboratories
      • 7.4.2.1. Clinical Laboratories Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Others
      • 7.4.3.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Neonatal Toxicology Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. North America
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ Reimbursement
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ Reimbursement
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ Reimbursement
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ Reimbursement
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Norway
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.9. Denmark
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework/ Reimbursement
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ Reimbursement
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ Reimbursement
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ Reimbursement
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ Reimbursement
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ Reimbursement
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework/ Reimbursement
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ Reimbursement
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ Reimbursement
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ Reimbursement
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ Reimbursement
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario
      • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. Quest Diagnostics Incorporated
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Others benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. USDTL
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Others benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Quidel Corporation
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Others benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Thermo Fisher Scientific, Inc.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Others benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Omega Laboratories, Inc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Others benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Bio-Rad Laboratories, Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Others benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Agilent Technologies, Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Others benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Laboratory Corporation of America Holdings
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Others benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Clinical Reference Laboratory, Inc.
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Others benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Cordant Health Solutions
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Others benchmarking
      • 9.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America neonatal toxicology market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 4 North America neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 5 North America neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 6 North America neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 7 U.S. neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 8 U.S. neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 9 U.S. neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 10 U.S. neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 12 Canada neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 13 Canada neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 14 Canada neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Mexico neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 16 Mexico neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 17 Mexico neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 18 Mexico neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe neonatal toxicology market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 21 Europe neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 22 Europe neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 23 Europe neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Germany neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 25 Germany neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 26 Germany neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 27 Germany neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 28 UK neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 29 UK neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 30 UK neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 31 UK neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 32 France neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 33 France neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 34 France neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 35 France neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Italy neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 37 Italy neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 38 Italy neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 39 Italy neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Spain neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 41 Spain neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 42 Spain neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 43 Spain neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Denmark neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 45 Denmark neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 46 Denmark neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 47 Denmark neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Sweden neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 49 Sweden neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 50 Sweden neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 51 Sweden neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Norway neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 53 Norway neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 54 Norway neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 55 Norway neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific neonatal toxicology market, by region, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 61 China neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 62 China neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 63 China neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 64 China neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Japan neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 66 Japan neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 67 Japan neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 68 Japan neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 69 India neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 70 India neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 71 India neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 72 India neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 73 South Korea neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 74 South Korea neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 75 South Korea neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 76 South Korea neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Australia neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 78 Australia neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 79 Australia neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 80 Australia neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Thailand neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 82 Thailand neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 83 Thailand neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 84 Thailand neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 85 Latin America neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 86 Latin America neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 87 Latin America neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 88 Latin America neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 89 Brazil neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 90 Brazil neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 91 Brazil neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 92 Brazil neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 93 Argentina neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 94 Argentina neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 95 Argentina neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 96 Argentina neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 97 MEA neonatal toxicology market, by region, 2018 - 2030 (USD Million)
  • Table 98 MEA neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 99 MEA neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 100 MEA neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 101 MEA neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 102 South Africa neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 103 South Africa neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 104 South Africa neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 105 South Africa neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 106 Saudi Arabia neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 110 UAE neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 111 UAE neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 112 UAE neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 113 UAE neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 114 Kuwait neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 115 Kuwait neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 116 Kuwait neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 117 Kuwait neonatal toxicology market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Neonatal toxicology market: market outlook
  • Fig. 14 Neonatal toxicology competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Neonatal toxicology market driver impact
  • Fig. 20 Neonatal toxicology market restraint impact
  • Fig. 21 Neonatal toxicology market strategic initiatives analysis
  • Fig. 22 Neonatal toxicology market: Specimen movement analysis
  • Fig. 23 Neonatal toxicology market: Specimen outlook and key takeaways
  • Fig. 24 Urine market estimates and forecast, 2018 - 2030
  • Fig. 25 Umbilical cord estimates and forecast, 2018 - 2030
  • Fig. 26 Meconium market estimates and forecast, 2018 - 2030
  • Fig. 27 Others market estimates and forecast, 2018 - 2030
  • Fig. 28 Neonatal toxicology Market: Technology movement analysis
  • Fig. 29 Neonatal toxicology market: Technology outlook and key takeaways
  • Fig. 30 Mass spectroscopy market estimates and forecasts, 2018 - 2030
  • Fig. 31 Immunoassay market estimates and forecasts,2018 - 2030
  • Fig. 32 Neonatal toxicology market: Drug movement analysis
  • Fig. 33 Neonatal toxicology market: Drug outlook and key takeaways
  • Fig. 34 Cannabinoids market estimates and forecast, 2018 - 2030
  • Fig. 35 Opioids estimates and forecast, 2018 - 2030
  • Fig. 36 Amphetamines market estimates and forecast, 2018 - 2030
  • Fig. 37 Cocaine market estimates and forecast, 2018 - 2030
  • Fig. 38 Benzodiazepines market estimates and forecast, 2018 - 2030
  • Fig. 39 Others illicit drugs market estimates and forecast, 2018 - 2030
  • Fig. 40 Neonatal toxicology market: End use movement analysis
  • Fig. 41 Neonatal toxicology market: End use outlook and key takeaways
  • Fig. 42 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 43 Clinical Laboratories market estimates and forecasts,2018 - 2030
  • Fig. 44 Others market estimates and forecasts, 2018 - 2030
  • Fig. 45 Global neonatal toxicology market: Regional movement analysis
  • Fig. 46 Global neonatal toxicology market: Regional outlook and key takeaways
  • Fig. 47 Global neonatal toxicology market share and leading players
  • Fig. 48 North America market share and leading players
  • Fig. 49 Europe market share and leading players
  • Fig. 50 Asia Pacific market share and leading players
  • Fig. 51 Latin America market share and leading players
  • Fig. 52 Middle East & Africa market share and leading players
  • Fig. 53 North America, by country
  • Fig. 54 North America
  • Fig. 55 North America market estimates and forecasts, 2018 - 2030
  • Fig. 56 U.S. key country dynamics
  • Fig. 57 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 58 Canada key country dynamics
  • Fig. 59 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 60 Mexico key country dynamics
  • Fig. 61 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 62 Europe
  • Fig. 63 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 64 UK key country dynamics
  • Fig. 65 UK market estimates and forecasts, 2018 - 2030
  • Fig. 66 Germany key country dynamics
  • Fig. 67 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 68 France key country dynamics
  • Fig. 69 France market estimates and forecasts, 2018 - 2030
  • Fig. 70 Italy key country dynamics
  • Fig. 71 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 72 Spain key country dynamics
  • Fig. 73 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 74 Denmark key country dynamics
  • Fig. 75 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 76 Sweden key country dynamics
  • Fig. 77 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 78 Norway key country dynamics
  • Fig. 79 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 80 Asia Pacific
  • Fig. 81 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 82 China key country dynamics
  • Fig. 83 China market estimates and forecasts, 2018 - 2030
  • Fig. 84 Japan key country dynamics
  • Fig. 85 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 86 India key country dynamics
  • Fig. 87 India market estimates and forecasts, 2018 - 2030
  • Fig. 88 Thailand key country dynamics
  • Fig. 89 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 90 South Korea key country dynamics
  • Fig. 91 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 92 Australia key country dynamics
  • Fig. 93 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 94 Latin America
  • Fig. 95 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 96 Brazil key country dynamics
  • Fig. 97 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 98 Argentina key country dynamics
  • Fig. 99 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 100 Middle East and Africa
  • Fig. 101 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 102 South Africa key country dynamics
  • Fig. 103 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 104 Saudi Arabia key country dynamics
  • Fig. 105 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 106 UAE key country dynamics
  • Fig. 107 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 108 Kuwait key country dynamics
  • Fig. 109 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 110 Market share of key market players - Neonatal toxicology market